title: Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
abstract: OBJECTIVE
  To assess long-term changes in lipids and lipoproteins concentrations associated with exposure to non-nucleoside reverse transcriptase inhibitors.
  
  
  METHODS
  Long-term analysis of plasma lipid concentrations was performed in patients starting first-line antiretroviral therapy with stavudine (d4T) and lamivudine, and either nevirapine or efavirenz.
  
  
  RESULTS
  Concentrations of total cholesterol, low-density lipoprotein cholesterol and triglycerides continued to increase, while high-density lipoprotein cholesterol showed a slight decrease compared with earlier reported increases after 48 weeks.
  
  
  CONCLUSIONS
  Changes in body fat distribution expected to occur with continued exposure to d4T could offer a potential explanation for these findings.
authors.affiliation: International Antiviral Therapy Evaluation Center, Amsterdam, the Netherlands. vanlethf@kncvtbc.nl
authors.forename: F
authors.initials: F
authors.lastname: van Leth
authors.forename: D B
authors.initials: DB
authors.lastname: Hall
authors.forename: J M A
authors.initials: JM
authors.lastname: Lange
authors.forename: P
authors.initials: P
authors.lastname: Reiss
mesh_terms: D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines; D002784:Cholesterol / Q000097:blood; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000175:diagnosis; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D019829:Nevirapine / Q000627:therapeutic use*; D010078:Oxazines / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D008055:Lipids; D008074:Lipoproteins; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D014280:Triglycerides; D019259:Lamivudine; D002784:Cholesterol; D019829:Nevirapine; D018119:Stavudine; C098320:efavirenz